Vytorin vs. Leqvio
See how Vytorin and Leqvio compare on approved uses, dosing, side effects, and cost.
Key Takeaways
Vytorin is a once-daily pill that combines two cholesterol-lowering mechanisms, while Leqvio is an injection given just twice a year after two starter doses.
Vytorin has clinical trial evidence for reducing heart attacks and strokes after a cardiac event, while Leqvio's approval is based on LDL-lowering data alone.
Both drugs lower LDL cholesterol, but Leqvio also has approval for adolescents 12 and older with familial hypercholesterolemia.
Vytorin vs. Leqvio Drug Summary
Vytorin
Vytorin combines ezetimibe, a cholesterol absorption inhibitor, with simvastatin, a statin, in one daily tablet. It lowers LDL cholesterol, total cholesterol, and triglycerides in adults with high cholesterol, including certain inherited forms. It also has trial evidence for reducing cardiovascular events after a heart attack.
Leqvio
Leqvio (inclisiran) is a PCSK9 synthesis inhibitor given as a subcutaneous injection that lowers LDL cholesterol by silencing a liver gene involved in cholesterol regulation. It is used alongside diet changes in adults with high cholesterol and in some inherited forms starting at age 12. After two starter doses, it only needs to be injected twice a year.
Vytorin vs. Leqvio Side Effects
Vytorin
Leqvio
Vytorin vs. Leqvio Dosage
Vytorin
Leqvio
| STAGE | DOSE | WHEN |
| Starting dose | 10 mg/10 mg once daily | At the start |
| Maximum dose | 10 mg/80 mg once daily | If needed |
| Dose changes | 3 increases | As tolerated |
| STAGE | DOSE | WHEN |
| Starting dose | 284 mg injection | Day 1 |
| Maximum dose | 284 mg injection | Same as starting |
| Dose changes | None | Fixed dose |
Vytorin
| STAGE | DOSE | WHEN |
| Starting dose | 10 mg/10 mg once daily | At the start |
| Maximum dose | 10 mg/80 mg once daily | If needed |
| Dose changes | 3 increases | As tolerated |
Leqvio
| STAGE | DOSE | WHEN |
| Starting dose | 284 mg injection | Day 1 |
| Maximum dose | 284 mg injection | Same as starting |
| Dose changes | None | Fixed dose |
Vytorin vs. Leqvio Indications
Vytorin
Vytorin is FDA approved to lower LDL cholesterol, total cholesterol, triglycerides, and Apo B in people with high cholesterol, and to raise HDL cholesterol. It is also approved for two rare inherited disorders: homozygous familial hypercholesterolemia and homozygous sitosterolemia.
Primary hyperlipidemia (high LDL, total cholesterol, triglycerides)
Raising HDL cholesterol
Homozygous familial hypercholesterolemia
Homozygous sitosterolemia
Leqvio
Leqvio is FDA approved as an add-on to diet and exercise to lower LDL cholesterol in adults with high cholesterol. It is also approved for heterozygous familial hypercholesterolemia in patients 12 and older, and for pediatric homozygous familial hypercholesterolemia starting at age 12.
Adjunct to diet and exercise for high LDL cholesterol
Heterozygous familial hypercholesterolemia (age 12+)
Pediatric homozygous familial hypercholesterolemia (age 12+)
Twice-yearly maintenance dosing after starter doses
Vytorin vs. Leqvio Pros and Cons
Vytorin
Vytorin is an oral option that pairs two cholesterol-lowering mechanisms in a single pill, and it is backed by outcomes data showing fewer heart attacks and strokes after a cardiac event. As a combination that includes a statin, it carries statin-specific risks like muscle pain and liver enzyme changes that Leqvio's non-statin mechanism avoids.
Pros
Oral tablet taken once daily, no injections
IMPROVE-IT trial showed fewer cardiovascular events post-heart attack
FDA approved for two rare inherited lipid disorders (HoFH, sitosterolemia)
Long-standing option, approved since 2004
Cons
Carries statin-related risks like myopathy and rhabdomyolysis
Contraindicated with strong CYP3A4 inhibitors, limiting drug combinations
Requires daily adherence rather than infrequent dosing
Not appropriate for active liver disease
Leqvio
Leqvio's twice-yearly injection schedule offers a dosing convenience that a daily pill can't match, which may help patients who struggle with adherence. Its siRNA mechanism sidesteps statin-related muscle and liver risks, but it lacks the cardiovascular outcomes data that Vytorin's statin component has generated.
Pros
Only two injections a year after initial starter doses
No statin-related muscle or liver enzyme risks
Approved for adolescents as young as 12 with familial hypercholesterolemia
Newer siRNA mechanism, distinct from statins and PCSK9 antibodies
Cons
No long-term cardiovascular outcomes data yet
Requires an in-office or self-administered injection rather than a pill
Risk of hypersensitivity reactions including anaphylaxis and angioedema
Not approved for homozygous FH in adults, only pediatric patients
Common Symptoms and Related Diseases You Can Explore
Explore a range of common symptoms the Doctronic Symptom Checker can help you understand.